Resverlogix Corp Presentation by Donald McCaffrey, President and CEO

Company: Resverlogix Corp
Website: www.resverlogix.com
Stock Symbol: TSX:RVX
Date Published: Sep 28, 2022

Resverlogix, a world leader in epigenetics, or gene regulation, announced that apabetalone’s future development related to COVID-19, will focus on the prevention and treatment of Post COVID-19 Conditions.	Resverlogix has begun enrollment and dosing of patients in a Phase 2b clinical trial at a site at the University of Alberta Hospital in Edmonton, to evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19	Resverlogix in active discussions with the Kingdom of Morocco’s Ministry of Health for the launch of COVID-19 clinical studies involving apabetalone
Resverlogix reported that its Apabetalone drug met its primary endpoint in a pulmonary arterial hypertension or ‘PAH’ investigator led pilot study	Resverlogix receives approval from Health Canada for its COVID-19 Clinical Trial Application for apabetalone